Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Bill Taaffe - aVenture Research

Bill Taaffe

AddedMar 31, 2024

UpdatedOct 16, 2026

Bill Taaffe

Bill Taaffe

Board Member, Strategikon Pharma

Bill Taaffe's Career

Strategikon Pharma

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Series A$25kSan Rafael, CA, US

Board Member· Board

Insight Genetics

$4.5MNashville, TN, US

Board Member· Board

Spencer Health Solutions

Series D$66.5MMorrisville, NC, US

Board Member· Board

ObjectiveHealth

Series A$13.6MFranklin, TN, US

Board Member· Board

ObvioHealth

Series B$61.9MNew York City, NY, US

Board Member· Board

People Similar to Bill Taaffe

Robert EpsteinBoard Member · Veracyte

Dr. Wei-Wu He Ph.D.Board Member · Genetron Health

Michael DentBoard Member · HealthLynked

Leadership at Strategikon Pharma

Paulo CarvalhoCo-Founder

Ineke RijnhoutBoard Member

Anca CopaescuCo-Founder

Mark DiianniBoard Member

Similar to Strategikon Pharma

Diligent PharmaPrinceton, NJ, USClinical Trial Softwareest. 2018Diligent PharmaPrinceton, NJ, US · est. 2018

Diligent: A cloud-based platform connecting clinical research sponsors with service providers for efficient trial starts.

Series A · $8.3M26

Leadership at Insight Genetics

Stephan MorrisFounder

Eric DahlhauserBoard Member

Similar to Insight Genetics

OncocyteIrvine, CA, USCancer Diagnosticsest. 2009OncocyteIrvine, CA, US · est. 2009

Oncocyte Corporation: A US-based molecular diagnostics firm, optimizing cancer care through accelerated diagnosis and treatment.

Public · $57.2M75

NeoGenomics LaboratoriesAliso Viejo, CA, USCancer Diagnosticsest. 2002NeoGenomics LaboratoriesAliso Viejo, CA, US · est. 2002

NeoGenomics: A clinical laboratory specializing in advanced cancer genetics diagnostic testing.

Public · $350.5M1.8k

Inform GenomicsBoston, MA, USDiagnostic Testsest. 2010Inform GenomicsBoston, MA, US · est. 2010

Inform Genomics develops personalized medicine products for cancer and inflammatory diseases, leveraging genomic studies to predict patient outcomes.

Seed · $3.1M30

VeracyteSouth San Francisco, CA, USOncology Testsest. 2006VeracyteSouth San Francisco, CA, US · est. 2006

Veracyte, Inc., based in South San Francisco, develops molecular oncology tests and provides diagnostic accuracy services.

Public · $681.3M787

Leadership at Spencer Health Solutions

Thomas RhoadsFounder

Mark GilreathBoard Member

Similar to Spencer Health Solutions

Spruce HealthSan Francisco, CA, USTelehealth, Virtual Careest. 2013Spruce HealthSan Francisco, CA, US · est. 2013

Spruce: Revolutionizing healthcare with our virtual doctor visit platform.

Inbound HealthMinneapolis, MN, USHealthcare, Home Healthest. 2022Inbound HealthMinneapolis, MN, US · est. 2022

Inbound Health: Full-stack provider enabling hospital and skilled nursing care at home.

Series B · $50M57

HealthSpotDublin, OH, USHealthcare, Telemedicineest. 2010HealthSpotDublin, OH, US · est. 2010

HealthSpot: Innovating healthcare access via technology. Our telemedicine platform connects patients and providers conveniently.

Series A · $54.2M175

MedArriveNew York City, NY, USHealthcare, Telemedicineest. 2020MedArriveNew York City, NY, US · est. 2020

MedArrive connects EMS professionals to patients at home, providing accessible, cost-effective healthcare via a holistic care platform.

Series C · $70.3M44

Leadership at ObjectiveHealth

Don LazasCo-Founder

Colleen HokeBoard Member

Similar to ObjectiveHealth

SiteBridge ResearchChapel Hill, NC, USClinical Researchest. 2021SiteBridge ResearchChapel Hill, NC, US · est. 2021

Empowering physicians and patients through clinical research for improved community health outcomes.

PulmonIxGreensboro, NC, USResearch Servicesest. 2016PulmonIxGreensboro, NC, US · est. 2016

An award-winning firm transforming clinical care through innovative research services.

ObvioHealthNew York City, NY, USClinical Trials, Softwareest. 2017ObvioHealthNew York City, NY, US · est. 2017

ObvioHealth: Digital clinical trial solutions provider, integrating smart devices for real-time studies.

Series B · $61.9M172

Elligo Health ResearchAustin, TX, USClinical Researchest. 2016Elligo Health ResearchAustin, TX, US · est. 2016

Elligo accelerates clinical research with direct access to 150M patients and efficient management solutions.

Series E · $196M443

Leadership at ObvioHealth

Similar to ObvioHealth

ClinOneNeedham, MA, USClinical Trialsest. 2016ClinOneNeedham, MA, US · est. 2016

ClinOne: Streamlining clinical trials with web and mobile solutions for improved patient experience.

Series A · $10.5M75

CurebaseSan Francisco, CA, USClinical Trials Softwareest. 2017CurebaseSan Francisco, CA, US · est. 2017

Curebase: Revolutionizing clinical trials with digital, accessible at-home research tools.

Series B · $57.5M175

Faro HealthSan Diego, CA, USClinical Trials Softwareest. 2019Faro HealthSan Diego, CA, US · est. 2019

Faro Health: Streamlining clinical trials with our cloud-native platform.

Series A · $35M42

Emvenio ResearchDurham, NC, USClinical Trialsest. 2020Emvenio ResearchDurham, NC, US · est. 2020

Emvenio Research: Enhancing clinical trial access through decentralized solutions for high-risk populations.

Series A · $9.2M52

Faro HealthSan Diego, CA, USClinical Trials Softwareest. 2019Faro HealthSan Diego, CA, US · est. 2019

Faro Health: Streamlining clinical trials with our cloud-native platform.

Series A · $35M42

Endpoint ClinicalSan Francisco, CA, USClinical Trial Softwareest. 2009Endpoint ClinicalSan Francisco, CA, US · est. 2009

Study software provider, Endpoint, designs and tests interactive data access platforms via phones.

MiracleSan Francisco, CA, USClinical Trial Softwareest. 2022MiracleSan Francisco, CA, US · est. 2022

Miracle: Streamlining clinical trials with an automated, integrated management platform.

Pre-Seed · $500k3